Quarterly report [Sections 13 or 15(d)]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

v3.25.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following is a summary of awards outstanding as of June 30, 2025 and 2024, which are not included in the computation of basic and diluted weighted average shares:
Three and six months ended
June 30,
2025 2024
Stock options (excluding exercisable penny stock options) 8,831,326  5,993,356 
Restricted stock units 283,411  283,411 
Warrants 5,827,031  5,152,397 
Total 14,941,768  11,429,164 
Schedule of Segment Reporting Information, by Segment In addition to the significant expense categories included within the total net loss presented on the Company's Statements of Operations, the following table sets forth significant segment expenses:
(in thousands) Three months ended June 30, Six months ended June 30,
2025 2024 2025 2024
Employee expenses $ 2,833  $ 2,324  $ 5,872  $ 4,882 
Research and Development (excluding employee expenses):
Consulting and professional fees 452  886  868  1,535 
Clinical study expenses 7  417  11  658 
Product development 647  363  1,356  559 
Other* 335  189  638  470 
Total Research and development expense $ 1,441  $ 1,855  $ 2,873  $ 3,222 
General and administrative expense (excluding employee expenses):
General and administrative expenses 592  757  1,325  1,531 
Commercialization readiness expenses 171  154  468  239 
Total General and administrative expense 763  911  1,793  1,770 
Total operating expenses $ 5,037  $ 5,090  $ 10,538  $ 9,874 

* Other primarily includes patent, and testing for three and six months ended June 30, 2025 and 2024.